From: Increased di-(2-ethylhexyl) phthalate exposure poses a differential risk for adult asthma clusters
Urinary metabolites | Severe/very severe vs. control (n = 36/33) | Mild/moderate vs. control (n = 44/33) | Atopic asthma vs. control (n = 66/131) | Non-atopic asthma vs. control (n = 14/131) | ||||||||
ORs | P-valuea | ORs | P-valuea | ORs | P-valueb | ORs | P-valueb | |||||
Model1 | MEHP | 1.38 | 0.07 | 1.33 | 0.10 | 1.56 | < 0.001* | 1.61 | 0.002* | |||
Model2 | MEHHP | 3.85 | < 0.001* | 3.60 | < 0.001* | 2.81 | < 0.001* | 3.19 | < 0.001* | |||
MEHHP/MEHP | 1.07 | 0.22 | 1.05 | 0.34 | 1.02 | 0.60 | 1.06 | 0.11 | ||||
Model3 | MEHP + MEHHP | 3.19 | < 0.001* | 2.98 | < 0.001* | 2.69 | < 0.001* | 3.04 | < 0.001* | |||
Urinary metabolites | Asthma/T2DM vs. control (5/33) | Asthma without T2DMvs control (n = 75/33) | Asthma/HPTS vs. control (n = 14/29) | Asthma without HPTS vs. control (n = 66/29) | ||||||||
ORs | P-valuec | ORs | P-valuec | ORs | P-valuec | ORs | P-valuec | |||||
Model1 | MEHP | 1.18 | 0.51 | 1.41 | 0.06 | 1.11 | 0.63 | 1.43 | 0.07 | |||
Model2 | MEHHP | 4.40 | < 0.001* | 4.45 | < 0.001* | 4.50 | 0.001* | 5.85 | < 0.001* | |||
MEHHP/MEHP | 1.10 | 0.16 | 1.06 | 0.27 | 1.14 | 0.04 | 1.06 | 0.33 | ||||
Model3 | MEHP + MEHHP | 3.18 | 0.003* | 3.51 | < 0.001* | 3.02 | 0.004* | 3.95 | < 0.001* | |||
Urinary metabolites | Asthma/T2DM/HPTS vs. control (n = 1/29) | Asthma without T2DM & HPTS vs. control (n = 62/29) | Asthma/allergic rhinitis vs. control (n = 52/27) | Asthma without allergic rhinitis vs. control (n = 28/27) | ||||||||
ORs | P-valuec | ORs | P-valuec | ORs | P-valuec | ORs | P-valuec | |||||
Model1 | MEHP | 0.70 | 0.41 | 1.39 | 0.15 | 2.01 | 0.03 | 1.62 | 0.06 | |||
Model2 | MEHHP | 5.36 | 0.01* | 7.02 | < 0.001* | 19.98 | < 0.001* | 10.62 | < 0.001* | |||
MEHHP/MEHP | 1.25 | 0.02 | 1.09 | 0.23 | 1.04 | 0.65 | 1.08 | 0.24 | ||||
Model3 | MEHP + MEHHP | 2.85 | 0.07 | 4.20 | < 0.001* | 10.47 | < 0.001* | 6.45 | < 0.001* |